EGFR vs. ALK: How molecular profiling defines lung cancer treatment
In today’s clinical oncology practice, the saying “no two cancers are alike” is more relevant than ever. I recently treated two patients with very similar advanced non-small cell lung cancer (NSCLC) who were both critically ill. However, molecular profiling revealed distinct genetic drivers for each case, leading to very different, highly customized treatment plans.
Patient presentation and initial assessment
Both patients, in their late 60s and never-smokers, presented with weight loss, worsening …
EGFR vs. ALK: How molecular profiling defines lung cancer treatment
